Structural MRI biomarkers for preclinical and mild Alzheimer's disease

Noninvasive MRI biomarkers for Alzheimer's disease (AD) may enable earlier clinical diagnosis and the monitoring of therapeutic effectiveness. To assess potential neuroimaging biomarkers, the Alzheimer's Disease Neuroimaging Initiative is following normal controls (NC) and individuals with mild cognitive impairment (MCI) or AD. We applied high‐throughput image analyses procedures to these data to demonstrate the feasibility of detecting subtle...